Adderall XR and Processing Speed in Multiple Sclerosis (MS)

This is an interventional treatment trial for Impaired Processing Speed focused on measuring Cognitive Impairment, Multiple Sclerosis, Processing Speed, Treatment Read More

Inclusion Criteria:

• - Males/Females who are ≥ 18 years old and ≤ 59 years old
• Relapsing Remitting, Secondary Progressive or Primary Progressive MS, as per revised McDonald's Criteria
• Have not received corticosteroids in last thirty days or a relapse in the last ninety days
• An Expanded Disability Status Scale (EDSS) of ≤ 6.5
• If female, must neither be pregnant nor breast-feeding

Exclusion Criteria:

• - Have evidence of other medical cause(s) of cognitive impairment
• Have evidence of major depression as determined by a positive Beck Depression Index-Fast screen ≥ 13and/or by clinician interview or evidence of severe fatigue with a Fatigue Severity Scale ≥ 5.
• Have demonstrated a hypersensitivity to amphetamines in the past
• Have uncontrolled or labile hypertension (> 135/85 mm Hg, treated or untreated)
• Have a history of structural heart disease, including atherosclerosis or angina
• Have a diagnosis of bipolar disorder or a history of a psychotic episode

• The following medications are not permitted to be used within 14 days the study

  1. Monoamine Oxidase Inhibitors
  2. Sympathomimetics or methadone
  3. Antipsychotic agents
  4. Modafinil

• The following medications are permitted if the dose has been stable for ≥ 28 days

  1. Short acting benzodiazepines, qhs administration only
  2. Anticonvulsants, including gabapentin and pregabalin
  3. Bupropion
  4. Tricyclic Antidepressants
  5. Anti-spasmodics such as baclofen or tizanidine
  6. Anticholinergic medication
  7. Selective serotonin(-norepinephrine) reuptake inhibitors